ONPATTRO (patisiran)
hATTR Amyloidosis with Polyneuropathy
ApprovedCommercial
Key Facts
Indication
hATTR Amyloidosis with Polyneuropathy
Phase
Approved
Status
Commercial
Company
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals' mission is to harness RNA interference (RNAi) to develop transformative medicines for patients with serious diseases. The company has achieved its goal of building a sustainable, top-tier biopharmaceutical company, with five FDA-approved products generating significant revenue and a deep clinical pipeline. Its strategy, 'Alnylam 2030,' focuses on expanding into prevalent diseases, advancing next-generation platforms, and scaling global commercial and manufacturing operations to serve millions of patients.
View full company profileTherapeutic Areas
Other hATTR Amyloidosis with Polyneuropathy Drugs
| Drug | Company | Phase |
|---|---|---|
| AMVUTTRA (vutrisiran) | Alnylam Pharmaceuticals | Approved |